Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Rafael Holdings ( (RFL) ) has shared an announcement.
On June 4, 2025, Rafael Holdings, Inc. announced the final results of its $25 million rights offering, which concluded on May 29, 2025. The offering resulted in subscriptions for 3,130,480 shares of Class B common stock, raising $4,007,014.40. CEO Howard S. Jonas and related parties will purchase the remaining unsubscribed shares for approximately $21 million through a backstop private placement. The total net proceeds from the rights offering and backstop purchase are estimated to be $24.9 million, which will support regulatory approval efforts and potential launch of Trappsol® Cyclo™.
Spark’s Take on RFL Stock
According to Spark, TipRanks’ AI Analyst, RFL is a Neutral.
Rafael Holdings’ overall score reflects significant financial challenges, including declining revenues and negative profitability, which weigh heavily on its financial performance. While the technical analysis also indicates bearish signals, the recent merger with Cyclo Therapeutics provides a potential positive outlook by strengthening strategic assets and leadership. However, the valuation remains unattractive with a negative P/E ratio. Overall, the company’s current financial struggles and weak technical indicators are only partially offset by recent strategic moves, resulting in a moderate stock score.
To see Spark’s full report on RFL stock, click here.
More about Rafael Holdings
Rafael Holdings, Inc. is involved in clinical and early-stage pharmaceutical ventures, including its wholly-owned subsidiary Cyclo Therapeutics, LLC, which is focused on developing Trappsol® Cyclo™, a treatment for Niemann-Pick Disease Type C1. The company also holds significant interests in LipoMedix Pharmaceuticals Ltd., Cornerstone Pharmaceuticals, Inc., Rafael Medical Devices, LLC, and Day Three Labs, Inc., spanning sectors from cancer therapeutics to medical devices and cannabis product innovation.
Average Trading Volume: 85,831
Technical Sentiment Signal: Sell
Current Market Cap: $74.8M
See more insights into RFL stock on TipRanks’ Stock Analysis page.